Sigyn Therapeutics Secures Funding via New Convertible Notes

Sigyn Therapeutics ( (SIGY) ) has issued an update.

On February 6 and February 12, 2026, Sigyn Therapeutics, Inc. entered into three one-year convertible note purchase agreements with Lambda Venture Partners, Brio Capital Master Fund and Osher Capital Partners, raising an aggregate of $61,500 in gross and net proceeds. The notes, which carry an 8% annual interest rate, are convertible at the investors’ option into common shares at a 35% discount to the lowest trading price over the preceding 20 trading days and were issued without warrants under a private placement exemption, introducing potential future equity dilution while providing short-term funding flexibility.

Spark’s Take on SIGY Stock

According to Spark, TipRanks’ AI Analyst, SIGY is a Underperform.

The overall score reflects significant financial challenges, including persistent net losses, high leverage, and no revenue growth. Technical indicators show mixed signals, with potential short-term upward momentum but risk of being overbought. The valuation is concerning with a negative P/E ratio, suggesting the stock is not a value play. The lack of clear communication in the earnings call adds to the uncertainty. Overall, the stock presents high risk with limited visibility into future improvements.

To see Spark’s full report on SIGY stock, click here.

More about Sigyn Therapeutics

Sigyn Therapeutics, Inc. is a U.S.-based company operating as a publicly traded corporation, as indicated by its issuance of convertible notes tied to its common stock. The firm raises capital through private placements with sophisticated institutional investors, reflecting a financing strategy reliant on structured securities rather than public equity offerings.

Average Trading Volume: 6,439

Technical Sentiment Signal: Sell

Current Market Cap: $1.2M

For an in-depth examination of SIGY stock, go to TipRanks’ Overview page.